DrugPatentWatch Database Preview
Novartis Pharms Corp Company Profile
What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?
There are one hundred and fifteen US patents protecting NOVARTIS PHARMS CORP drugs.
There are one thousand eight hundred and thirty-two patent family members on NOVARTIS PHARMS CORP drugs in sixty-eight countries and one hundred and seventy supplementary protection certificates in fifteen countries.
Summary for Novartis Pharms Corp
| International Patents: | 1832 |
| US Patents: | 115 |
| Tradenames: | 52 |
| Ingredients: | 43 |
| NDAs: | 60 |
Drugs and US Patents for Novartis Pharms Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114-003 | May 29, 2013 | RX | Yes | Yes | 9,155,706 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Novartis Pharms Corp | ZOFRAN | ondansetron hydrochloride | TABLET;ORAL | 020103-002 | Dec 31, 1992 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-001 | Jan 27, 1999 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Novartis Pharms Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | ZOFRAN PRESERVATIVE FREE | ondansetron hydrochloride | INJECTABLE;INJECTION | 020007-003 | Dec 10, 1993 | 5,578,628*PED | ➤ Sign Up |
| Novartis Pharms Corp | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | 5,955,488*PED | ➤ Sign Up |
| Novartis Pharms Corp | ARRANON | nelarabine | INJECTABLE;IV (INFUSION) | 021877-001 | Oct 28, 2005 | 5,424,295 | ➤ Sign Up |
| Novartis Pharms Corp | ZOFRAN | ondansetron hydrochloride | TABLET;ORAL | 020103-001 | Dec 31, 1992 | 5,344,658*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARMS CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Ophthalmic Suspension | 0.3% | ➤ Subscribe | 2015-12-21 |
| ➤ Subscribe | Ophthalmic Solution | 0.10% | ➤ Subscribe | 2006-07-17 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
| ➤ Subscribe | Oral Solution | 4 mg/5 mL | ➤ Subscribe | 2004-12-20 |
| ➤ Subscribe | Nasal Spray | 0.665 mg/ Spray | ➤ Subscribe | 2009-06-29 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | Tablets | 50 mg and 75 mg | ➤ Subscribe | 2014-01-07 |
| ➤ Subscribe | Ophthalmic Emulsion | 0.05% | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Ophthalmic Solution | 0.7% | ➤ Subscribe | 2015-09-10 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
| ➤ Subscribe | Ophthalmic | 0.50% | ➤ Subscribe | 2005-12-22 |
| ➤ Subscribe | Ophthalmic Solution | 0.003% | ➤ Subscribe | 2015-12-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.20% | ➤ Subscribe | 2008-09-08 |
| ➤ Subscribe | Ophthalmic Solution | 0.00% | ➤ Subscribe | 2009-02-19 |
| ➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2011-03-14 |
| ➤ Subscribe | Ophthalmic Solution | 10.5% | ➤ Subscribe | 2012-02-29 |
| ➤ Subscribe | Tablets | 12.5 mg and 25 mg | ➤ Subscribe | 2014-02-04 |
| ➤ Subscribe | Otic Suspension | 0.3%/0.1% | ➤ Subscribe | 2012-07-31 |
Non-Orange Book US Patents for Novartis Pharms Corp
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,822,685 | 2,4-pyrimidinediamine compounds and their uses | ➤ Sign Up |
| 7,754,733 | Crystalline topotecan hydrochloride product and process for making the same | ➤ Sign Up |
| 7,517,886 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | ➤ Sign Up |
| 6,838,449 | Ophthalmic compositions containing galactomannan polymers and borate | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Novartis Pharms Corp Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2282636 | ➤ Sign Up |
| China | 101232880 | ➤ Sign Up |
| Eurasian Patent Organization | 017405 | ➤ Sign Up |
| Hungary | S1600024 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Novartis Pharms Corp Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0018 | France | ➤ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN,SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN,C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL) PROPIONATE-(S)-3'-METHYL-2'-(PENTANOY(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE)DE TRISODIUM HEMIPENTAHYDRATE; REGISTRATION NO/DATE: EU/1/15/1058 20151123 |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: PASIREOTID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/12/753/001-017 IDF DER ENTSCHEIDUNG DER KOMMISSION C (2014) 8916 20141119 |
| 00111 | Netherlands | ➤ Sign Up | PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| 0811 | Netherlands | ➤ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN, MET INBEGRIP VAN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/15/1058 (C(2015) 8288) 20151123 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
